Using the same set of melanoma tissue microarrays, we found that BRAF expression and MMP2 expression are the best markers for AJCC Stages I and II, respectively, whereas p27 cytoplasm expression is a superior prognostic marker for patients in both Stages III and IV. Here, CDKN1B is linked to melanoma.